SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001193125-23-080505
Filing Date
2023-03-27
Accepted
2023-03-27 16:30:54
Documents
7

Document Format Files

Seq Description Document Type Size
1 DEFA14A d448803ddefa14a.htm DEFA14A 19454
2 GRAPHIC g448803txs1g1.jpg GRAPHIC 138299
3 GRAPHIC g448803txs2g1.jpg GRAPHIC 429992
4 GRAPHIC g448803txs3g1.jpg GRAPHIC 329509
5 GRAPHIC g448803txs4g1.jpg GRAPHIC 380059
6 GRAPHIC g448803txs5g1.jpg GRAPHIC 329271
7 GRAPHIC g448803txs6g1.jpg GRAPHIC 118723
  Complete submission text file 0001193125-23-080505.txt   2398209
Mailing Address 245 FIRST STREET CAMBRIDGE MA 02142
Business Address 245 FIRST STREET CAMBRIDGE MA 02142 617-871-2098
Akebia Therapeutics, Inc. (Filer) CIK: 0001517022 (see all company filings)

IRS No.: 208756903 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-36352 | Film No.: 23764892
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences